中生方政NBF品牌怎么样 申请店铺

我要投票 中生方政NBF在医疗器械行业中的票数:459 更新时间:2025-06-29
中生方政NBF是哪个国家的品牌?「中生方政NBF」是 中生方政生物技术股份有限公司 旗下著名品牌。该品牌发源于江苏省泰州市,由创始人郭光华在2009-09-22期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力中生方政NBF品牌出海!将品牌入驻外推网,定制中生方政NBF品牌推广信息,可以显著提高中生方政NBF产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

中生方政NBF怎么样

中生方政生物技术股份有限公司,成立于2009年,是一家集诊断试剂、生物医药、预防性疫苗及仪器设备的研发和生产为一体的生物医药技术企业。占地面积近55000平方米,建筑面积25700 平方米。研发总部设立在美国,主要从事具有国际前沿技术水平的体外诊断试剂的开发和研制。已建成核酸分子诊断试剂生产车间、金标车间、酶联免疫诊断试剂生产车间、中试(设备)车间、动力中心、动物实验楼、综合楼(研发中心)等标准化GMP生产车间及现代化办公配套设施,现已完成规模化产业基地的建设,形成了年产分子诊断试剂1000万人份和分子检测设备1000台的生产能力。

中生方政长期专注于临床分子诊断技术的开发。在国内IVD行业,中生方政是为数不多拥6项以上注册文号的生产企业,实现了产品价格多层次化,产品结构梯队化,可以满足不同客户的检测需求和价格承受能力,具有较宽的市场辐射面,为市场纵深开发打下了良好基础。

作为前沿技术创新主导型高科技企业,公司依托自主研发及联合开发等多种方式,创建了成熟稳定的新型核酸检测技术平台,并已先期开发出人乳头瘤病毒(HPV)临床检测试剂,成为国内首个利用恒温技术检测HPV病毒的产品。目前公司已获得国家食品药品监督总局颁发的15种型别人乳头瘤病毒和16/18型人乳头瘤病毒核酸检测试剂盒(恒温扩增-荧光法)、人乳头瘤病毒(HPV)基因分型检测试剂盒(恒温扩增-荧光法)、人乳头瘤病毒(HPV)核酸检测试剂盒(恒温扩增-荧光法)等产品注册证书。同时,公司还开发出配套的恒温荧光检测设备。依托于该技术平台,公司正在努力拓展产品线,逐步推进试剂和仪器的“系列化”、“一体化”发展目标。

中生方政将本着“用心、专注、创新、服务”的企业理念和“成为国内在体外诊断试剂产业领域最具创新研发能力的优秀产品与服务供应商”的发展愿景,“资本加创新”双轮驱动的发展战略,以及“质量第一 追求卓越”的管理理念,愿同社会各界合作共赢,回馈股东、客户和员工,进而为推动我国医学检验产业及健康医疗事业的发展做出新的贡献。


Zhongsheng Fangzheng Biotechnology Co., Ltd., founded in 2009, is a biomedical technology enterprise integrating research and development and production of diagnostic reagents, biomedicine, preventive vaccines and equipment. It covers an area of nearly 55000 square meters and a building area of 25700 square meters. R & D headquarters is established in the United States, mainly engaged in the development and development of in vitro diagnostic reagents with international cutting-edge technology level. Standardized GMP production workshops and modern office facilities have been built, such as nucleic acid molecular diagnostic reagent production workshop, gold standard workshop, enzyme-linked immunodiagnostic reagent production workshop, pilot test (equipment) workshop, power center, animal laboratory building, comprehensive building (R & D center). The construction of large-scale industrial base has been completed, with an annual output of 10 million people and molecules of molecular diagnostic reagents Production capacity of 1000 testing equipment. Zhongsheng Fangzheng has long focused on the development of clinical molecular diagnosis technology. In the domestic IVD industry, Zhongsheng Fangzheng is one of the few manufacturers with more than 6 registered numbers. It has realized multi-level product price and echelon product structure, which can meet the testing needs and price tolerance of different customers. It has a wide market radiation and lays a good foundation for in-depth market development. As a leading high-tech enterprise of cutting-edge technology innovation, the company has established a mature and stable new nucleic acid detection technology platform relying on independent research and development and joint development, and has developed the clinical detection reagent of human papillomavirus (HPV) in advance, becoming the first domestic product using constant temperature technology to detect HPV virus. At present, the company has obtained product registration certificates issued by the State Food and drug administration, such as 15 types of HPV and 16 / 18 HPV nucleic acid detection kits (constant temperature amplification fluorescence method), HPV gene typing detection kits (constant temperature amplification fluorescence method), HPV nucleic acid detection kits (constant temperature amplification fluorescence method), etc Book. At the same time, the company also developed a complete set of constant temperature fluorescence detection equipment. Relying on this technology platform, the company is striving to expand its product line and gradually promote the development goals of "serialization" and "integration" of reagents and instruments. Zhongsheng Fangzheng is willing to cooperate with all walks of life for win-win cooperation and feedback with the corporate philosophy of "heart, focus, innovation and service", the development vision of "becoming the best product and service provider with the most innovative R & D ability in the field of in vitro diagnostic reagent industry in China", the development strategy of "capital plus innovation" driven by two wheels, and the management concept of "quality first pursuit of excellence" Shareholders, customers and employees will make new contributions to the development of China's medical testing industry and health care industry.

本文链接: https://brand.waitui.com/2c7dece2d.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

成都先导:终止收购南京海纳医药科技约65%股权事项

成都先导公告,公司原拟以现金方式受让股权的方式合计取得南京海纳医药科技股份有限公司约65%的股权。《股权收购意向书》签署后,公司积极组织交易各方推进本次交易,聘请了专业的中介机构对标的公司展开尽调,在此基础上,交易各方对本次交易方案进行多次论证和协商,但未能就本次交易事项的核心条款达成一致意见。 为切实维护公司及全体股东利益,经公司充分审慎研究并与交易对方友好协商,交易各方一致同意终止本次交易事项,本次重大资产重组事项终止。

2小时前

磁谷科技股东宝利丰拟减持,不超过总股本3%

6月29日,磁谷科技公告显示,股东南京宝利丰创业投资合伙企业(有限合伙)因自身资金安排,拟通过集中竞价、大宗交易的方式减持其持有的公司股份不超过2,149,569股。减持不超过公司总股本的3.00%。

2小时前

中信证券:中报季还是以结构性机会为主,预计AI和军工是三季度寻找结构性机会的重心

近日,中信证券研报指出,从板块轮动来看,活跃资金或正从医药和消费切向科技和金融,红利也开始滞涨。结构性机会仍料将是贯穿中报季的话题,指数型机会可能还需要等三季度末到四季度。预计AI和军工是三季度寻找结构性机会的重心。(财联社)

2小时前

*ST金刚:孙公司金刚数智签订3.99亿元重大算力销售合同

6月29日,*ST金刚发布公告称,公司下属孙公司北京金刚数海智算科技有限公司(简称“金刚数智”)于2025年6月27日与江苏***大数据有限公司(简称“算力客户”)签订了《智算中心多元算力服务项目之服务协议》。由金刚数智向算力客户提供算力服务,合同含税总金额3.99亿元,服务期限5年,按月度支付算力服务费用。

2小时前

紫光国微:6月27日以4961.73万元回购77.55万股公司股份

6月29日,紫光国微发布公告称,6月27日公司通过股份回购专用证券账户以集中竞价交易方式实施了首次回购(以下简称“本次回购”)。回购公司股份数量77.55万股,约占公司目前总股本的0.09%,最高成交价为64.28元/股,最低成交价为63.67元/股,成交金额为4961.73万元(不含交易费用)。本次回购资金来源为公司自有资金,回购价格未超过前述回购公司股份方案的规定。

2小时前

本页详细列出关于中生方政NBF的品牌信息,含品牌所属公司介绍,中生方政NBF所处行业的品牌地位及优势。
咨询